Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

The article states that Annamycin has strengthened its global intellectual-property estate for a proprietary liposomal formulation designed to target lung metastases. The development may support long-term commercialization and competitive protection for the oncology candidate, although no patent jurisdiction, financial terms, clinical data, or regulatory milestones were disclosed.